Immunologist With Breakthrough Research Is Praising Synthetic Cannabis

By , in Health on . Tagged width: ,

Synthetic cannabis is in the spotlight these days again.

A medical pioneer whose amazing research regarding inflammation led to the development of some of the world’s top-selling drugs is nor reportedly embracing medical marijuana, according to the latest reports coming from BNN Bloomberg.

Marc Feldmann is an immunologist who supported the discovery of a new class of drugs that includes Remicade and Humira. He co-founded CannBioRex Pharmaceuticals, a Toronto-based company researching the potential medical uses of synthetic cannabis.

Massive potential in synthetic cannabis 

As you probably already know, the medical marijuana regulations in the U.S. and also around the globe are easing up, and Feldmann said that cannabis could become the basis for a new class of drugs to treat pain and other conditions.

“There is massive potential, but it’s not yet understood,” Feldmann said in an interview. “It’s never been tested properly.”

Feldmann and co-founder Raphael Mechoulam, an Israeli chemist, known for his work with the compounds found in cannabis, started to experiment with using marijuana to treat inflammation in the late 1990s, and they found out that it worked on mice.

BNN Bloomberg also notes that this came right after Feldmann made a massive breakthrough that helped develop drugs in order to treat various health conditions such as rheumatoid arthritis, inflammatory bowel disease and more.

Despite good results, there’s still lack of support 

The early results with medical pot have been more than promising but they lack support.

“We couldn’t find any support,” Feldmann said. “It made no sense, but at some point, you gracefully give up and move on.”

GW Pharmaceuticals, a British company, has created the first marijuana-derived drug to be approved by the U.S. FDA, and the medical pot is now legal in more than 30 states.

Feldmann said the new company would need to raise at least $100 million to conduct the research and trials necessary to get a cannabis-based drug to market.

He believes that synthetic cannabis is the key to a new class of drugs, and not natural pot.